SAN DIEGO/PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP™. The AJICAP technology allows developers of therapeutic Antibody Drug Conjugates (ADCs) to better control both the location of payload conjugation to an antibody along with fine tuning the quantity of payload attached. Conventional ADCs which are currently commercially available are produced as heterogeneous mixtures containing a stochastic distribution of payloads decorating the antibody molecules. The controlling of the Drug-to-Antibody Ratio (DAR) in the development of next generation ADCs is believed to assist in increasing the therapeutic window of these targeted biologics leading to overall better clinical efficacy and less toxicity.
The AJICAP technology was developed within Ajinomoto's Research and Development organization in Kawasaki, Japan. Aji Bio-Pharma presented data obtained via internal research as well as partnerships with biopharmaceutical companies. The data presented shows that deployment of the AJICAP technology in preparation of ADCs demonstrated enhancement of the therapeutic window by achieving a site-specific DAR of 2 with native antibodies when compared to stochastic ADCs which contain a mixture of DAR species. The data also showed a wide drug-linker compatibility and reactive group compatibility including thiol and azide functionalities. In addition, the Ajinomoto Bio-Pharma team demonstrated that the technology could be scaled to produce gram quantities of ADCs for pre-clinical testing.
Brian Mendelsohn, Ph.D., Director of ADC Process Development and Tech Transfer at Aji Bio-Pharma, states "the AJICAP technology utilizes a proprietary affinity peptide to direct controlled conjugation to the antibody in a relatively straight-forward synthetic process. This is technology that can easily be transferred to the manufacturing floor since it shows high productivity and short conjugation reaction times, which all lead to an ease of manufacture. We have demonstrated with model ADCs and utilizing client provided materials that the technology is effective and scalable."
Aji Bio-Pharma provides ADC process development, analytical, drug substance and drug product manufacturing services from its recently constructed facility in San Diego, CA.
Jason Brady, Ph.D., Sr. Director Business Development, states, "this is the next step in Ajinomoto Bio-Pharma's service offering to our clients. The AJICAP platform developed by our Ajinomoto colleagues in Japan provides our clients access to site-specific conjugation technology that can be coupled with our process development and manufacturing services in San Diego, CA. We look forward to introducing the technology to our client base interested in ADCs and other products requiring bioconjugation."
Tatsuya Okuzumi, Ph.D., Associate General Manager of R&D Planning at Ajinomoto states "the demonstration of feasibility of the first generation AJICAP technology has been successful. We are now working to improve the platform in order to broaden the scope of capabilities including additional conjugation sites on the antibody. We look forward to presenting updates at future meetings."
